Stefan Meister is Group Chief Operating Officer of the Waypoint Group, a business enterprise for the managers and advisers of the funds and investments associated with the Bertarelli family. Prior to that, he was Chief Financial Officer of the Haniel Group, before which he was a member of the Executive Management Board of Celesio Group. He began his career in 1991 at Novartis AG (Switzerland), holding various positions including Head of Controlling for the Pharma Division. Stefan Meister is a Member of the Advisory Board of the Centre for Leadership and Value in Society at the University of St. Gallen, a Member of the “Schweizer Dialog” and an active member of the World Economic Forum’s Family Business Community. Until May 2016, he was a Member of the Board of Directors of the Swiss group, Straumann. Stefan Meister is Swiss and holds a degree in economics from Basel University
Michele Antonelli has more than 20 years of international experience in the biopharmaceutical industry with extensive expertise in both manufacturing and commercial.
Michele Antonelli previously worked at UCB where he held roles of various responsibility and scope, most recently serving as Executive Vice President and Head of lmmunology Europe, overseeing the region’s commercial, medical, and market access activities.
Prior to joining UCB, Michele Antonelli spent 16 years at Merck Serono, ultimately serving as Senior Vice President and Global Head of Biotech Manufacturing and Process Development.
He is Swiss and Italian, and graduated as Doctor in Sciences from University of Bari. He trained in Biotechnology at Catholic University in Piacenza and at Iowa State University in Ames, Iowa.
Rodolfo Bogni is chairman of Northill UK, a director of Waypoint Capital Holdings and a trustee of the Prince of Liechtenstein Foundation and of LGT. Mr Bogni is a member of the Governing Council of the Centre for the Study of Financial Innovation, the Advisory Board of Oxford Analytica and the Council of Shakespeare’s Globe Theatre. He is also a member of the Securities Institute, the London Mathematical Society and the Vereinigung Basler Oekonomen. Rodolfo Bogni started his banking career in the early 1970s with the Chase Manhattan Bank. He was later the Group Treasurer of the Midland Bank and then Chief Executive Officer, Private Banking of UBS. Mr Bogni has also served as Senior Independent Director of Old Mutual plc, a trustee of Fondazione Bruno Kessler, an independent director of Moody’s (U.K., France and Germany) and a trustee of Common Purpose Charitable Trust. He is Italian and graduated as doctor in economics and business administration at Università L Bocconi, Milan.
Dr. Sophie Kornowski joined Gurnet Point Capital in 2018 from Roche where she was Executive Vice-President of Roche Partnering. In that role she focused on establishing external partnerships with biotechnology and research institutions worldwide for Roche Holding AG, one of the world’s largest healthcare companies. She was also a member of Roche's Extended Global Executive Committee. Dr. Kornowski and her team completed over 50 deals per year in her role as head of partnering at Roche. Previously, she led Roche's major affiliate for five years in France. Dr. Kornowski also spent 11 years in various leadership roles at Merck in the United States, France and Israel. She spent the early years of her career at Abbott and Sanofi, in France and the United States. She has an MBA from the University of Chicago Booth and a PhD in Pharmacy from Paris Descartes University.
. By continuing your visit on the website, you consent to the use of the cookies.
YOU ARE LEAVING THE WWW.STALLERGENESGREER.COM WEBSITE